Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer
NCT05576389Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2022
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and camrelizumab in breast cancer, sponsored by Peking University People's Hospital. Primary endpoint: Total Pathological Complete Response at 6 months. Started Oct 2022; status: recruiting.
02
Drugs
fluzoparibcamrelizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05576389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576389.